Cox 2 Selective Inhibitor

Cox 2 Selective Inhibitor Information

Rofecoxib belongs to the group of NSAIDs known as COX-2 selective inhibitors or coxibs (CycloOXygenase-2 Inhibitors). Being COX-2 selective means that these drugs act specifically on one form of the cyclooxygenase (COX) enzyme, namely the COX-2, whereas previous NSAIDs inhibited both COX-1 and COX-2. This specificity allows rofecoxib and other COX-2 inhibitors to reduce inflammation and pain while minimizing undesired gastrointestinal adverse effects - peptic ulcers - that are common with non-selective NSAIDs such as aspirin, naproxen, and ibuprofen.

Interestingly, at the time of its withdrawal, rofecoxib was the only coxib with clinical evidence of its superior gastrointestinal adverse effect profile over conventional NSAIDs. This was largely based on the VIGOR (Vioxx GI Outcomes Research) study, which compared the efficacy and adverse effect profiles of rofecoxib and naproxen. (Bombardier et al., 2000).

More on Vioxx (Rofecoxib):

• COX-2 Selective Inhibitor

• Vioxx Adverse Drug Reactions

• Vioxx Market Withdrawal

• Vioxx FDA Health Advisory

For more free legal information on Dangerous Drugs Lawsuits, please use the links below:

• Vioxx Lawsuit

• Fen-Phen Lawsuit

• Bextra Lawsuit